Covid-19 vaccine: Bharat Biotech told to submit complete phase-2 data before phase-3 trial
The vaccine candidate - 'Covaxin' - is being indigenously developed by the Bharat Biotech in collaboration with ICMRRepresentational Image

Covid-19 vaccine: Bharat Biotech told to submit complete phase-2 data before phase-3 trial

As per officials, Bharat Biotech applied to the DCGI on Oct. 2, seeking its permission to conduct phase-3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine candidate

Bharat Biotech, which had been awaiting Drugs Controller General of India's (DCGI) nod for conducting phase-3 clinical trials of its COVID-19 vaccine candidate, has been asked to first submit complete safety and immunogenicity data of the ongoing phase-2 trial, besides providing some clarifications, before proceeding for the next stage.

The vaccine candidate - 'Covaxin' - is being indigenously developed by the Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

The Hyderabad-based vaccine maker, according to the officials, applied to the DCGI on October 2, seeking its permission to conduct phase-3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine candidate.

The firm in its application said that the study would cover 28,500 subjects aged 18 years and above and would be conducted in 19 sites, including Delhi, Mumbai, Patna and Lucknow, across 10 states.

"The company presented phase-3 clinical trial protocol along with interim data of phase 1 and 2 clinical trials," an official said.

The vaccine candidate - 'Covaxin' - is being indigenously developed by the Bharat Biotech in collaboration with ICMR
Second Russian vaccine on its way, but why is Moscow rushing?

The subject expert committee (SEC) at the Central Drugs Standard Control Organisation (CDSCO) deliberated on the application on October 5.

"After a detailed deliberation, the committee opined that the design of the phase-3 study is in principle satisfactory except for clarification on definition of asymptomatic, etc.

"However, the study should be initiated with appropriate dose identified from the phase-2 safety and immunogenicity data. Accordingly, the firm should submit safety and immunogenicity data from phase-2 trial for consideration," the panel said in its recommendations.

The SEC during its discussion also observed that the vaccine was well-tolerated in all dose groups and no serious adverse events have been reported so far, a source stated.

"The most common adverse event was pain at the injection site, which resolved transiently. The phase-3 clinical trial application proposed a dose of 0.5 ml on day 0 and 28," the source added.

The vaccine candidate - 'Covaxin' - is being indigenously developed by the Bharat Biotech in collaboration with ICMR
Digital divide: Online schooling in Nagaland amid COVID-19 pandemic

For more such stories, follow us on Facebook, Twitter and Instagram. Activate Website Notifications to stay updated.

Related Stories

EastMojo
www.eastmojo.com